Michael Attal
#146,389
Most Influential Person Now
Michael Attal's AcademicInfluence.com Rankings
Michael Attalphilosophy Degrees
Philosophy
#7897
World Rank
#11177
Historical Rank
Logic
#4930
World Rank
#6268
Historical Rank
Download Badge
Philosophy
Why Is Michael Attal Influential?
(Suggest an Edit or Addition)Michael Attal's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma (1996) (2706)
- International uniform response criteria for multiple myeloma (2006) (2014)
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. (2007) (1389)
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. (2012) (1017)
- Single versus double autologous stem-cell transplantation for multiple myeloma. (2003) (1015)
- A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. (1996) (932)
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. (2007) (879)
- Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial (2007) (874)
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma (2017) (776)
- Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma (2008) (764)
- Heterogeneity of genomic evolution and mutational profiles in multiple myeloma (2014) (743)
- International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders (2009) (718)
- Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. (2014) (666)
- Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. (2006) (662)
- Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. (2016) (582)
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (2019) (555)
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (2010) (523)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (2019) (520)
- International uniform response criteria for multiple myeloma (2006) (519)
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. (2017) (441)
- Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). (2010) (413)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2010) (378)
- Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. (2000) (374)
- Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. (2008) (355)
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. (2006) (355)
- Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. (2006) (354)
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma (2009) (347)
- Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. (2003) (343)
- Bone marrow mesenchymal stem cells are abnormal in multiple myeloma (2007) (320)
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (2019) (316)
- International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. (2011) (295)
- Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. (2011) (285)
- Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2017) (279)
- Prognostic significance of copy-number alterations in multiple myeloma. (2009) (261)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. (2018) (254)
- Frontline therapy of multiple myeloma. (2015) (249)
- Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome. (2014) (241)
- Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments] (1992) (230)
- Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. (2013) (228)
- Prognostic factors for survival and response after high‐dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients (1998) (222)
- The role of complete response in multiple myeloma. (2009) (217)
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (2013) (216)
- VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. (2016) (214)
- Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. (1992) (213)
- Increased and highly stable levels of functional soluble interleukin‐6 receptor in sera of patients with monoclonal gammopathy (1993) (210)
- Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. (2017) (202)
- International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100) (2009) (202)
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. (2008) (198)
- Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. (2018) (195)
- IMWG consensus on maintenance therapy in multiple myeloma. (2012) (191)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients (2000) (189)
- Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. (2002) (186)
- Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. (2008) (185)
- Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. (2006) (184)
- Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. (2020) (184)
- Autologous haematopoietic stem cell transplants for autoimmune disease – feasibility and transplant-related mortality (1999) (180)
- Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. (1994) (179)
- Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. (2012) (176)
- Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma (2006) (174)
- Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project (2013) (172)
- Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. (2009) (163)
- Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells (1999) (159)
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (2010) (157)
- Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle. (1999) (155)
- Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. (1995) (153)
- Intensive combined therapy for previously untreated aggressive myeloma. (1992) (151)
- Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences. (2010) (149)
- Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM) (2000) (148)
- Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. (1998) (148)
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone (2010) (146)
- Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death. (2014) (144)
- International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation (2009) (143)
- Survival and years of life lost in different age cohorts of patients with multiple myeloma. (2010) (142)
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma (2010) (137)
- American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip (2015) (134)
- Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM). (1995) (128)
- Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. (2011) (126)
- Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. (1990) (124)
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? (2011) (124)
- Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation (2003) (124)
- Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle (1996) (123)
- Study of Lenalidomide Plus Dexamethasone Versus Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma (MM): Results of a Phase 3 Study (MM-010). (2005) (122)
- The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia (2009) (118)
- Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma (2010) (116)
- Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. (2011) (116)
- Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study. (1996) (116)
- Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial) (2015) (115)
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement (2011) (114)
- Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the french registry on autologous transplantation in multiple myeloma (1995) (114)
- Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. (2010) (113)
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years (2015) (108)
- Long-term follow-up results of IFM99-03 and IFM99-04 trials comparing nonmyeloablative allotransplantation with autologous transplantation in high-risk de novo multiple myeloma. (2008) (107)
- High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. (2012) (100)
- Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. (2015) (100)
- Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. (1995) (100)
- Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. (2013) (98)
- Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02. (2010) (98)
- In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma (1991) (97)
- Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. (2013) (96)
- Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. (2006) (94)
- Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter? (2015) (94)
- Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. (1999) (94)
- Automated Extraction and Quantification of Human Cytomegalovirus DNA in Whole Blood by Real-Time PCR Assay (2003) (94)
- Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome. (2001) (94)
- A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial (2019) (92)
- Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. (2012) (90)
- Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). (2007) (88)
- A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. (1996) (87)
- Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial. (1993) (87)
- Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia (2000) (87)
- Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials (2007) (86)
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). (2002) (85)
- Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial (2008) (85)
- Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. (2015) (85)
- VELCADE/Dexamethasone (Vel/D) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantion (ASCT) in Newly Diagnosed Multiple Myeloma (MM): Updated Results of the IFM 2005/01 Trial. (2007) (84)
- Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients (2012) (81)
- Multiple myeloma clonal evolution in homogeneously treated patients (2018) (81)
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (81)
- Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. (2001) (80)
- Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival (2011) (80)
- Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma. (2019) (78)
- The role of autologous hematopoietic stem cell transplantation in multiple myeloma. (1997) (77)
- Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission. (2000) (76)
- Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. (2000) (75)
- VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. (2006) (74)
- Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. (2008) (69)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
- Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. (1995) (67)
- Double Vs Single Autologous Stem Cell Transplantation After Bortezomib-Based Induction Regimens For Multiple Myeloma: An Integrated Analysis Of Patient-Level Data From Phase European III Studies (2013) (67)
- Lenalidomide maintenance after transplantation for myeloma. (2010) (66)
- Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. (1992) (66)
- Familial multiple myeloma: report of fifteen families (1999) (66)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (64)
- Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial (2015) (63)
- Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. (2018) (63)
- Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. (1991) (62)
- Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. (2018) (62)
- Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS). (2016) (61)
- Major Superiority of Melphalan - Prednisone (MP) + Thalidomide (THAL) over MP and Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Elderly Patients with Multiple Myeloma. (2005) (61)
- Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT) (2013) (60)
- The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT (2013) (59)
- Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis (2018) (59)
- Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma (2020) (58)
- Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma. (2016) (57)
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma (2013) (56)
- Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. (2008) (55)
- Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. (2000) (55)
- Genomics of Multiple Myeloma. (2017) (54)
- Thalidomide in patients with advanced multiple myeloma. (2000) (53)
- A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. (1998) (52)
- Higher incidence of relapse with peripheral blood rather than marrow as a source of stem cells in adults with acute myelocytic leukemia autografted during the first remission. (2009) (51)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (50)
- Maintenance Treatment with Thalidomide after Autologous Transplantation for Myeloma : First Analysis of a Prospective Randomized Study of the Intergroupe Francophone du Myelome (IFM 99 02). (2004) (50)
- How I treat first relapse of myeloma. (2017) (50)
- Large‐scale expansion and transplantation of CD34+ hematopoietic cells: in vitro and in vivo confirmation of neutropenia abrogation related to the expansion process without impairment of the long‐term engraftment capacity (2006) (50)
- Randomized trial experience of the Intergroupe Francophone du Myélome. (2001) (50)
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. (2022) (49)
- Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience. (2005) (49)
- Improved outcome for AML patients over the years 2000–2014 (2017) (49)
- The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. (1997) (49)
- Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial (2020) (49)
- Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma. (2018) (48)
- Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID‐19 (2020) (48)
- Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. (2015) (48)
- Higher incidence of relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. (2010) (46)
- Standard therapy versus autologous transplantation in multiple myeloma. (1997) (45)
- The role of stem cell transplantation in multiple myeloma. (2002) (44)
- A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial (2018) (43)
- Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial (2017) (43)
- Autologous stem cell transplantation (2004) (42)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
- Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Preliminary Results of an IFM Phase II Study (2005) (42)
- Evaluation of AMG 420, an anti-BCMA bispecific T-cell engager (BiTE) immunotherapy, in R/R multiple myeloma (MM) patients: Updated results of a first-in-human (FIH) phase I dose escalation study. (2019) (42)
- Prophylaxis of invasive aspergillosis with voriconazole or caspofungin during building work in patients with acute leukemia (2010) (42)
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. (2009) (41)
- Frontline Therapy with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Induction Followed By Autologous Stem Cell Transplantation, Krd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma (NDMM) Patients: Primary Results of the Intergroupe Francophone Du MyéLome (IFM) Kr (2016) (41)
- Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma. (1997) (41)
- Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma (2018) (40)
- Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005–01 trial (2010) (39)
- High Complete and Very Good Partial Response Rates with Bortezomib—Dexamethasone as Induction Prior to ASCT in Newly Diagnosed Patients with High-Risk Myeloma: Results of the IFM2005-01 Phase 3 Trial. (2009) (39)
- Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle. (1996) (39)
- The CD24 antigen discriminates between pre-B and B cells in human bone marrow. (1990) (38)
- Erratum: International uniform response criteria for multiple myeloma (Leukemia (2006) vol. 20 (1467-1473) 10.1038/sj.leu.2404284) (2006) (37)
- Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC) (2005) (37)
- Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. (1993) (37)
- Prevention of acute GVHD by in vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. (1991) (37)
- Bortezomib (VELCADE®) Plus Dexamethasone as Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: Preliminary Results of an IFM Phase II Study. (2004) (37)
- Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation. (1994) (37)
- Poly(phosphorhydrazone) dendrimers: yin and yang of monocyte activation for human NK cell amplification applied to immunotherapy against multiple myeloma. (2016) (37)
- Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities. (1993) (36)
- Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM) (2009) (35)
- Prospective Evaluation of MRI and PET-CT at Diagnosis and before Maintenance Therapy in Symptomatic Patients with Multiple Myeloma Included in the IFM/DFCI 2009 Trial (2014) (35)
- Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation (2001) (35)
- Deciphering the chronology of copy number alterations in Multiple Myeloma (2019) (35)
- Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion (2004) (34)
- Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. (1991) (34)
- Myeloperoxidase: an enzyme involved in intrinsic vincristine resistance in human myeloblastic leukemia. (1993) (34)
- The Prognostic Impact of Complete Remission (CR) Plus Very Good Partial Remission (VGPR) in a Double-Transplantation Program for Newly Diagnosed Multiple Myeloma (MM). Combined Results of the IFM 99 Trials. (2006) (32)
- Expressed fusion gene landscape and its impact in multiple myeloma (2017) (32)
- Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. (1993) (32)
- Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study. (2010) (32)
- Hairy cell transformation of a B-cell chronic lymphocytic leukemia: a morphological, cytochemical, phenotypic and molecular study. (1991) (32)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (32)
- Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients (2014) (31)
- High‐dose therapy in multiple myeloma: A prospective randomized study of the “intergroupe français du myelome” (1995) (31)
- Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand? (2015) (30)
- International uniform response criteria for multiple myeloma (2007) (30)
- In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction. (1992) (29)
- Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia (1997) (29)
- Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study (2010) (28)
- Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients. (2004) (27)
- Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials. (2006) (27)
- Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): a new tool for the assessment of minimal residual disease in follicular lymphomas (1996) (27)
- High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02 (2011) (26)
- Enhanced activation of B cells in a granulocyte colony‐stimulating factor‐mobilized peripheral blood stem cell graft (2001) (25)
- LEADING ARTICLE International uniform response criteria for multiple myeloma (2006) (25)
- Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. (1991) (25)
- Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program (2011) (24)
- Hepatic veno-occlusive disease following bone marrow transplantation treated by prostaglandin E1. (1991) (24)
- Role of autologous stem-cell transplantation in multiple myeloma. (2007) (24)
- Hemolytic‐Uremic syndrome in a patient with chronic myelogenous leukemia treated with interferon alpha (1994) (24)
- Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (2016) (24)
- Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. (2019) (23)
- Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. (2011) (23)
- Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02) (2017) (23)
- Is There Still a Place for Total Body Irradiation (TBI) In the Conditioning Regimen of Autologous Stem Cell Transplantation In Mantle Cell Lymphoma ?: a Retrospective Study From the Lymphoma Working Party of the EBMT (2010) (23)
- Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14) (2013) (23)
- Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myélome-Midi-Pyrénées Group. (1996) (23)
- A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. (2012) (22)
- Preliminary Results from a Phase I Study of Isatuximab (ISA) in Combination with Bortezomib, Lenalidomide, Dexamethasone (VRd), and in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Non-Eligible for Transplant (2018) (22)
- Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Joined Analysis of Two Prospective Randomized Phase III Trials (2018) (21)
- Lack of efficacy of clarithromycin in advanced multiple myeloma (1999) (21)
- Prevention of Regimen-Related Toxicities After Bone Marrow Transplantation by Pentoxifylline: A Prospective, Randomized Trial (1993) (21)
- The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma (2011) (21)
- Phase 2 Study of 2 Modalities of Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. IFM 2009-02 (2010) (20)
- Heavy/Light Chain Specific Immunoglobulin Ratios at Presentation Are Prognostic for Progression Free Survival in the IFM 2005-01 Myeloma Trial. (2009) (20)
- Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients (2017) (20)
- Impact of Cytogenetics on Outcomes of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone in the First (MM-020) Trial (2015) (19)
- Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma (1996) (19)
- Bortezomib, Thalidomide and Dexamethasone (VTD) Is Superior to Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Prior to Autologous Stem Cell Transplantation for Patients with De Novo Multiple Myeloma. Results of the Prospective IFM 2013-04 Trial (2015) (19)
- High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma. (1998) (19)
- t(14;14)(q11;q32) in biphenotypic blastic phase of chronic myeloid leukemia. (1986) (19)
- Autologous stem cell transplantation versus chemotherapy for adult patients with acute myeloid leukemia in first remission: the BGMT Group experience. (1993) (19)
- Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine. (1994) (18)
- Leuconostoc, a potential pathogen in bone marrow transplantation (1993) (18)
- Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM Study (2018) (18)
- Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. (2012) (18)
- Lenalidomide (L) in Combination with Dexamethasone (D) Improves Survival and Time to Progression in Elderly Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM). (2006) (18)
- Long-Term Maintenance with Lenalidomide Improves Progression Free Survival In Myeloma Patients with High-Risk Cytogenetics: An IFM Study (2010) (17)
- Final Analysis of Overall Survival from the First Trial (2016) (17)
- Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA (2019) (17)
- Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients. (2013) (17)
- New developments in conditioning regimens before auto-SCT in multiple myeloma (2011) (17)
- Early intensification followed by allo-BMT or auto-BMT or a second intensification in adult ALL: a randomized multicenter study. (1992) (17)
- A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). (2019) (17)
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome (IFM) (2016) (17)
- Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements (2018) (17)
- Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma (2014) (17)
- A pilot study of autologous bone marrow transplantation followed by recombinant interleukin-2 in malignant lymphomas. (1996) (17)
- Is there a place for blood stem-cell transplantation for the younger adult patient with acute myelogenous leukemia? BGMT Group. (1994) (16)
- Lenalidomide in Combination with Dexamethasone Is More Effective Than Dexamethasone at First Relapse in Relapsed Multiple Myeloma. (2006) (16)
- Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies (2012) (16)
- Association of the Philadelphia chromosome and 5q- in secondary blood disorder. (1988) (16)
- The Translocation t(4;14) Can Be Present Only in Minor Subclones in Multiple Myeloma (2013) (16)
- Lenalidomide After Autologous Transplantation for Myeloma: First Analysis of a Prospective, Randomized Study of the Intergroupe Francophone Du Myelome (IFM 2005 02). (2009) (16)
- Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) (2015) (16)
- Logic programming reveals alteration of key transcription factors in multiple myeloma (2017) (16)
- Increased vascularization in myeloma (2001) (16)
- The role of high-dose therapy with autologous stem cell support in the era of novel agents. (2009) (16)
- Impact of Chromosomal Abnormalities Del(13), T(4;14), and Del(17p) and Prior Treatment on Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Lenalidomide (2008) (15)
- Autologous peripheral blood progenitor cell transplantation for multiple myeloma. (1999) (15)
- Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype (2006) (15)
- Stem-cell transplantation in multiple myeloma. (2005) (15)
- Novel DNA polymerase mutations conferring cytomegalovirus resistance: input of BAC-recombinant phenotyping and 3D model. (2013) (15)
- Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study. (1991) (14)
- bcl‐2 proto‐oncogene and Epstein–Barr virus latent membrane protein‐1 expression in AIDS‐related lymphoma (1994) (14)
- Antineutrophil cytoplasmic antibodies (ANCA) in chronic graft-versus-host disease after allogeneic bone marrow transplantation (1997) (14)
- The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients (2014) (14)
- One versus two high‐dose cytarabine‐based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission (2005) (14)
- Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma (2020) (14)
- Vitamin D deficiency does not alter biochemical markers of bone metabolism before or after autograft in patients with multiple myeloma (2010) (13)
- One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy (2018) (13)
- Potential strategies for circumventing myeloperoxidase-catalyzed degradation of vinca alkaloids. (1994) (13)
- Variable BCL2/BCL2L1 ratio in multiple myeloma with t(11;14). (2018) (13)
- Impact of FISH and Cytogenetics On Overall and Event Free Survival in Myeloma: An IMWG Analysis of 9,897 Patients. (2009) (13)
- Increased vascularization in myeloma. (2001) (13)
- Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. (1991) (13)
- Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial (2019) (12)
- Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma. (2016) (12)
- DKK1 and sclerostin are early markers of relapse in multiple myeloma. (2017) (12)
- Induction with Velcade®/Dexamethasone Partially Overcomes the Poor Prognosis of t(4;14), but Not That of Del(17p), in Young Patients with Multiple Myeloma. (2009) (12)
- PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE BY MONOCLONAL ANTIBODY TO INTERLEUKIN-2 RECEPTOR (1989) (12)
- All transplantation-eligible patients with myeloma should receive ASCT in first response. (2014) (12)
- Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma (2018) (12)
- Comparison of Sebia Free Light Chain Assay With Freelite Assay for the Clinical Management of Diagnosis, Response, and Relapse Assessment in Multiple Myeloma. (2019) (11)
- Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination before and after Autologous Stem Cell Transplantation (ASCT) Followed By Ixazomib Maintenance Is a Safe and Effective Strategy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du MyéLome ( (2017) (11)
- 1p22 and 1p32 Deletions Are Independent Prognosis Factors in Young Patients with Myeloma: The IFM Experience On 1195 Patients (2012) (11)
- Efficacy of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial. (2019) (11)
- Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. (2013) (11)
- Dual‐energy X‐ray absorptiometry and biochemical markers of bone turnover after autologous stem cell transplantation in myeloma (2012) (11)
- Bortezomib (BOR) and High Dose Melphalan (HDM) as Conditioning Regimen Before Autologous Stem Cell Transplantation (ASCT) for De Novo Multiple Myeloma (MM): Final Results of the IFM Phase II Study VEL/MEL (2008) (10)
- Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation (2014) (10)
- Outcome of Adult Patients with Acute Myeloid Leukemia who Failed to Achieve Complete Remission after one Course of Induction Chemotherapy: A Report from the BGMT Study Group: For the BGMT (2001) (10)
- Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group. (1991) (10)
- S824 A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF ISATUXIMAB, POMALIDOMIDE, AND LOW-DOSE DEXAMETHASONE VS POMALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) (2019) (10)
- A Comprehensive Analysis of Cytogenetic Abnormalities in Myeloma: Results of the FISH Analysis of 1000 Patients Enrolled in the IFM99 Trials. (2005) (10)
- Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against (2017) (10)
- Epstein‐Barr virus in familial Hodgkin's disease (1994) (10)
- Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES (2013) (10)
- Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation. (1994) (10)
- KAPOSI'S SARCOMA‐ASSOCIATED HERPESVIRUS (KSHV) IN BONE MARROW BIOPSY FROM PATIENTS WITH MULTIPLE MYELOMA: PCR AMPLIFICATION OF ORF26 BUT NOT ORF72 AND ORF75 SEQUENCES (2000) (9)
- Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes. (1994) (9)
- Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma. (1997) (9)
- Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia : a matter of controversies (2001) (9)
- Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma (2018) (9)
- The efficacy and safety of lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma patients with impaired renal function (2008) (9)
- Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results. (2021) (9)
- Kaposi's sarcoma‐associated herpesvirus (KSHV) in bone marrow biopsies of patients with Waldenstrom's macroglobulinaemia (1998) (9)
- P980 Liposomal amphotericin B standard dose in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocom-promised patients: randomised pilot study (Combistrat Trial) (2007) (8)
- Prospective randomized study of GVHD prevention using an anti IL2 receptor (CD25) MoAb after allogeneic bone marrow transplantation (BMT). (1991) (8)
- Using Poisson–gamma model to evaluate the duration of recruitment process when historical trials are available (2017) (8)
- Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial (2016) (8)
- DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in Multiple Myeloma (2010) (8)
- Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results. (2019) (8)
- Vincristine degradation by serum from leukemic patients: role of myeloperoxidase. (1996) (8)
- Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis (2019) (8)
- Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients (2014) (8)
- Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma (2015) (8)
- Prospective Study Comparing Idarubicin and Daunorubicin in Elderly Patients with Acute Myeloid Leukemia (1992) (8)
- B-cell lymphoma following polycythemia vera: evidence for the involvement of two different clones. (1994) (8)
- Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). (2012) (7)
- Trisomy 11 in acute myeloid leukemia: ten cases. (1994) (7)
- Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma (2010) (7)
- Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM (2021) (7)
- Dual-energy X-ray absorptiometry in patients with multiple myeloma and benign gammopathies. (1996) (7)
- Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab Plus Pomalidomide and Dexamethasone: Icaria-MM Study (2019) (7)
- Evolution of peripheral blood T lymphocyte subsets after allogenic or autologous hematopoietic stem cell transplantation. (2014) (7)
- ICARIA-MM study: efficacy analysis according to prior lines of treatment (2019) (7)
- Integrated Analysis of Bortezomib-Lenalidomide-Dexamethasone vs Bortezomib-Thalidomide-Dexamethasone in Transplant-Eligible Newly Diagnosed Myeloma (2019) (7)
- Does more intensive treatment cure more patients with acute myeloid leukemia? The BGMT Group. (1991) (7)
- O95 Treatment of advanced multiple myeloma (MM) with thalidomide (THAL). Long term follow-up in a prospective study of 121 patients (2003) (7)
- Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk (2020) (6)
- Stem cell transplantation in multiple myeloma. (2007) (6)
- Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma. (2010) (6)
- Dasatinib in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Study. (2009) (6)
- Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response (2016) (6)
- A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone (2017) (6)
- [Association of idiopathic lymphedema and familial acute leukemia. Apropos of a new case]. (1985) (6)
- Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells (2020) (6)
- Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis (2019) (6)
- Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma (2015) (6)
- Symptomatic osteonecrosis in recipients of nonautologous bone marrow transplants. (1995) (6)
- Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients. (2012) (6)
- The Future Role of Thalidomide in Multiple Myeloma (2005) (5)
- S825 EVALUATION OF AMG 420, AN ANTI-BCMA BISPECIFIC T-CELL ENGAGER (BITE®) IMMUNOTHERAPY, IN R/R MULTIPLE MYELOMA (MM) PATIENTS: UPDATED RESULTS OF A FIRST-IN-HUMAN (FIH) PHASE 1 DOSE ESCALATION STUDY (2019) (5)
- PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD): PHASE 3 CASSIOPEIA STUDY (2019) (5)
- Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03 (2019) (5)
- Short‐ and long‐term outcomes of AL amyloidosis patients admitted into intensive care units (2016) (5)
- Flow cytometric characterization of proliferating natural killer lymphocytes from bone marrow donors in the mixed lymphocyte reaction. (1998) (5)
- Alternative Splicing Is a Frequent Event and Impacts Clinical Outcome in Myeloma: A Large RNA-Seq Data Analysis of Newly-Diagnosed Myeloma Patients (2014) (5)
- LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS. MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL (2014) (5)
- Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT (2008) (5)
- Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and/or refractory multiple myeloma (RRMM). (2016) (5)
- Safety and Efficacy Outcomes with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma Were Not Significantly Different for the Treatment of Patients with or without High-Risk Disease or Elderly Status (2008) (5)
- Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis (2019) (5)
- Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) (2015) (5)
- Impact of age on efficacy and safety of daratumumab in combination with lenalidomide and dexamethasone (D-Rd) in patients (pts) with transplant-ineligible newly diagnosed multiple myeloma (NDMM): MAIA. (2019) (5)
- The Impact of Lenalidomide, Bortezomib, and Dexamethasone Treatment on Health-Related Quality of Life in Transplant-Eligible Patients with Newly-Diagnosed Multiple Myeloma: Results from the IFM/DFCI 2009 Trial (2018) (5)
- Deletion of the 17p Chromosomal Region Is Associated with a Very Poor Outcome in Multiple Myeloma Independently of the Type of Treatment. (2009) (4)
- Multiple myeloma in the era of novel agents. (2009) (4)
- MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial (2020) (4)
- Updates from a phase Ib study of isatuximab (Isa), bortezomib (V) and dexamethasone (D) plus cyclophosphamide (C) or lenalidomide (R) in transplant-ineligible, newly diagnosed multiple myeloma (NDMM). (2020) (4)
- A phase III, randomized, open-label study of isatuximab (SAR650984) plus pomalidomide (Pom) and dexamethasone (Dex) versus Pom and Dex in relapsed/refractory multiple myeloma. (2017) (4)
- Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT (2014) (4)
- The current landscape of multiple myeloma treatment. (2008) (4)
- Effect of melphalan against self-renewal capacity of leukemic progenitors in acute myeloblastic leukemia. (1992) (4)
- A Matching-Adjusted Indirect Comparison (MAIC) of Daratumumab-Bortezomib-Thalidomide-Dexamethasone (D-VTd) Versus Bortezomib-Lenalidomide-Dexamethasone (VRd) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (2019) (4)
- Heterogeneity in long term outcomes for R-ISS stage II in newly diagnosed multiple myeloma patients. (2022) (4)
- Multiple Myeloma Drivers of High Risk and Response to Stem Cell Transplantation Identified By Causal Machine Learning: Out-of-Cohort and Experimental Validation (2017) (4)
- Allografting or autografting for myeloma. (2007) (4)
- Serum Free Light Chains Should be the Target of Response Evaluation in Light Chain Multiple Myeloma Rather Than Urines: Results from the IFM/DFCI 2009 Trial (2014) (4)
- Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma (2019) (4)
- [Initial antibacterial prophylaxis after bone marrow allograft. Pilot study with systemic vancomycin]. (1988) (4)
- Very early allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission A report from the Societe Francaise de Greffe de Moelle (1994) (4)
- DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma (2020) (4)
- Growth factor‐associated graft‐versus‐host disease and mortality 10 years after allogeneic bone marrow transplantation (2012) (3)
- Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort (2022) (3)
- Immunohistochemical detection of multidrug resistance associated P-glycoprotein in stromal cells of malignant lymphomas. (1990) (3)
- Light Chain Escape in Multiple Myeloma (2018) (3)
- The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) (2011) (3)
- PS1377 IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY (2019) (3)
- Stem Cell Factor (SCF) for Hematopoietic Stem Cell (HSC) Mobilization: Results of the Randomized IFM 99-01 Trial. (2004) (3)
- Posterior reversible encephalopathy syndrome: two cases in young adults with acute lymphoblastic leukemia. (2009) (3)
- Prolonged Overall Survival with Pomalidomide and Dexamethasone in Myeloma Characterized with End Stage Disease. (2012) (3)
- A Novel Evolutionary Pattern Revealed Using Deep Sequencing of Immunoglobulin Loci at Diagnosis and over the Course of Treatment in Multiple Myeloma Patients (2016) (3)
- Consolidation with Bortezomib, Thalidomide and Dexamethasone After High Dose Therapy Is Feasible, Safe and Effective In De Novo Multiple Myeloma Patients Who Already Received New Drugs Containing-Induction Regimen (2010) (3)
- High-dose therapy in multiple myeloma. (2002) (3)
- Landscape of Recurrent Mutations in Non-Coding Genome with Functional Implications in Newly-Diagnosed Multiple Myeloma (2018) (3)
- Free Light Chain Escape in Multiple Myeloma : an Exceptional Phenomenon (2016) (3)
- Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA (2019) (3)
- Long-term follow-up of autotransplant (AT)-supported high-dose melphalan (hdm) for multiple myeloma (MM): Update of Intergroup Francophone du Myelome (IFM), Southwest Oncology Group (SWOG), and Arkansas (ARK) Total Therapy (TT) trials. (2009) (3)
- Maintenance therapy for myeloma: how much, how long, and at what cost? (2012) (3)
- Low Level Of NF-Kb Activity Is Associated With Higher Response Rate To Bortezomib-Based Induction Therapy In Patients With Newly Diagnosed Multiple Myeloma (2013) (3)
- myeloma autologous stem cell transplantation in newly diagnosed multiple thalidomide plus dexamethasone as induction treatment before Bortezomib plus dexamethasone versus reduced-dose bortezomib, (2012) (3)
- Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma (2004) (2)
- Characterization of Mesenchymal Stem Cells Abnormalities in Multiple Myeloma. (2006) (2)
- Identification Rate of Myeloma-Specific Clonotypes in Multiple Diagnostic Sample Types from Patients with Multiple Myeloma Using Next-Generation Sequencing Method (2014) (2)
- Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS) (2017) (2)
- S874 EFFICACY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA BASED ON MINIMAL RESIDUAL DISEASE STATUS: ANALYSIS OF CASSIOPEIA (2019) (2)
- A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE) (2019) (2)
- The Level of AKT Phosphorylation on Threonine 308 but Not on Serine 473 Is Associated with High-Risk Cytogenetics and Predicts Poor Overall Survival in Acute Myeloid Leukemia. (2008) (2)
- Multiple Myeloma (MM): Impact of Immunoglobulin Isotype on the Speed of Response (2015) (2)
- Deep Sequencing of Immunoglobulin Loci Reveals Evolution of IgH Clone in Multiple Myeloma Patients over the Course of Treatment (2014) (2)
- Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. (2019) (2)
- Use of Recombinant Interleukin-2 (RU 49637) After Autologous Bone Marrow Transplantation in Patients with Hematological Disease: Phase I–II Study (1992) (2)
- Impact on Survival Outcomes of Bone Marrow Plasma Cells Percentage and Morphology Evaluation By Conventional Microscopy in Multiple Myeloma after High Dose Therapy (2014) (2)
- Uterine chloroma, aortic thrombus and CALM/AF10 acute myeloid leukemia. (2010) (2)
- [Detection of residual disease in follicular lymphomas using the PCR technique: importance of clono-specific probes]. (1998) (2)
- The anti-BCMA Bispecific T-cell Engager (BiTE®) Molecule AMG 420 Induced MRD-Negative Complete Responses in R/R Multiple Myeloma in a FIH study (2019) (2)
- Hevylite® to Monitor Response to Therapy in Multiple Myeloma (2014) (2)
- Magnetic resonance imaging findings in multiple myeloma: description and predictive value (2001) (2)
- Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study (2012) (2)
- Bortezomib and high-dose melphalan as conditioning regimen before transplantation for de novo multiple myeloma patients: Updated data of the IFM phase II study. (2010) (2)
- Do new therapeutic approaches (autotransplants, thalidomide, dexamethasone) improve the survival of patients with multiple myeloma followed in a rheumatology department? (2006) (2)
- Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study (2020) (2)
- Hevylite® to Monitor Hypogammaglobulinemia, a Predictor of Response to Therapy in Multiple Myeloma (2014) (2)
- Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. (2022) (2)
- Use of recombinant IL-2 (RU49637) after autologous bone marrow transplantation (BMT) in patients with hematological neoplasias: a phase 1 study. (1991) (2)
- Impact Of Consolidation With Bortezomib-Thalidomide-Dexamethasone (VTd) Upfront In Multiple Myeloma (MM) With Partial Response (PR) At Completion Of Induction With Vtd (2013) (1)
- All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study (2022) (1)
- A Detailed Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2016) (1)
- Adult Acute Lymphoblastic Leukemia — Results of the French AALL 87 Protocol with Different Strategies of Postremission Therapy (1994) (1)
- S145 PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D-VTD) VERSUS VTD IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PART 1 CASSIOPEIA RESULTS (2019) (1)
- Blood by Real-Time PCR Assay Human Cytomegalovirus DNA in Whole Automated Extraction and Quantification of (2003) (1)
- The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies (2019) (1)
- standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma Intensive conventional chemotherapy (ACVBP regimen) compared with (2009) (1)
- High-Resolution Genomic Profiles Identify Novel Genes and/or Chromosomal Regions with Prognostic and Oncogenic Significance in Myeloma Patients. (2007) (1)
- Heterogeneity in long-term outcomes for patients with Revised International Staging System stage II, newly diagnosed multiple myeloma (2022) (1)
- A Genome-Wide Association Study Identi fi es a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma (2016) (1)
- Proceedings of an educational symposium at the 34th Annual Meeting of the European Group for Blood and Marrow Transplantation 30 March 2008 Florence, Italy Lenalidomide in multiple myeloma: in pursuit of optimal treatment (2008) (1)
- Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (2010) (1)
- Early and Late Intravenous Interleukin-2 Infusion after Autologous Bone Marrow Transplantation: Report of Multicentric French Studies1 (1994) (1)
- Non-Myeloablative Allogeneic Hematopoietic Transplantation in Relapsed/Primary Refractory Follicular Lymphoma. (2004) (1)
- PF594 BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE VS BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION: INTEGRATED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (2019) (1)
- Factors Influencing Outcome in De Novo Myelodysplastic Syndromes Treated by Allogeneic Bone Marrow Transplantation: A Long-Term Study (2002) (1)
- Comparison of two conditioning regimens in allogeneic bone marrow transplantation (ABMT): Emphasis on the role of total body irradiation (TBI) for “high risk” patients (1997) (1)
- Maintenance with Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (IFM 2012-03) (2019) (1)
- Matched Unrelated Donor Transplantation Is Curative In Selected Patients with Diffuse Large B Cell Lymphoma: A Report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT) (2010) (1)
- Carfilzomib weekly-melphalan-prednisone in untreated elderly multiple myeloma: IFM2012-03. (2017) (1)
- Comparing the Performance of Serum Free Light Chain Measurements with Urine Electrophoresis and Immunofixation for Monitoring and Assessing Response to Therapy in Patients with Multiple Myeloma (2014) (1)
- Detection of minimal residual disease in follicular lymphomas using PCR : value of clonospecific probes (1998) (1)
- Polyclonal Immunoglobulin Recovery is Enhanced After Autologous Stem Cell Transplant and Associates with Improved Clinical Outcomes in Multiple Myeloma Patients (2017) (1)
- Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation (RIC allo-SCT) for Patients with High-Risk Multiple Myeloma (MM): A Survey from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire. (2008) (1)
- Efficacy of Lenalidomide in Patients with Multiple Myeloma Previously Treated by Melphalan-Prednisone and Thalidomide (2012) (1)
- Quantifying the transient response of bedrock channels to Active Normal Faulting: New Field Observations (2005) (1)
- Long-Term Exposure to Pomalidomide-Dexamethasone in Pts with Refractory Myeloma (2014) (1)
- Interleukin-2 (IL-2) After Autologous Bone Marrow Transplantation (BMT):A Pilot Study of Late Administration, 2–3 Months Post ABMT (1990) (1)
- Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma (2015) (0)
- Treatment for elderly patients with multiple myeloma – Authors' reply (2008) (0)
- In Vitro and in Vivo Enhancement of Ricin-A Chain Immunotoxin Novel Indoli/ine Calcium Channel Blockers: Delayed Intracellular Degradation Linked to Lipidosis Induction1 (2006) (0)
- Phase 1/2 study of car fi lzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma (2015) (0)
- (IFM) myeloma: a phase 2 study of the Intergroupe Francophone du Myélome autologous stem cell transplantation in patients with de novo multiple Bortezomib and high-dose melphalan as conditioning regimen before (2013) (0)
- MULTIPLE MYELOMA: FROM THE BENCH TO BEDSIDE Frontline therapy of multiple myeloma (2015) (0)
- Comparison o f H igh-Dose T herapy a nd A utologous S tem-Cell Transplantation W ith C onventional T herapy f or H odgkin's Disease I nduction F ailure: A C ase-Control S tudy (1999) (0)
- The Interpretation of a Treaty by a National Jurisdiction (2007) (0)
- 5.33 Choosing Best Option for Patients > 65 years with Chronic Lymphocytic Leukemia: Balancing Disease Status and Comorbidities in an Unselected Community-Based Population (2011) (0)
- Early Allogeneic Bone Marrow Transplantation for Young Adults with Acute Myeloid Leukemia in First Complete Remission: The 17 Year Experience of the BGMT Group. (2004) (0)
- Consolidation with Vtd Significantly Improves the Complete Remission (CR) Rate Following Vtd Induction and Single Autologous Stem Cell Transplantation (auto) in Multiple Myeloma (MM). (2012) (0)
- In Vitro and in Vivo Enhancement of Ricin-A Chain Immunotoxin Activity by Novel Indoli / ine Calcium Channel Blockers : Delayed Intracellular Degradation Linked to Lipidosis Induction 1 (2006) (0)
- Responses Assigned Using Heavy+Light Chain Assessments Have Better Clinical Correlation with Outcome Than Those Using Current IMWG Criteria for Multiple Myeloma (2016) (0)
- [Autograft and multiple myeloma: experience of the Intergroupe Français du Myélome]. (2001) (0)
- OP53 Autologous versus allogenic stem cell transplantation for multiple myeloma (2007) (0)
- Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome (2019) (0)
- Serum Free Light Chain Responses Have Greater Concordance with Clinical Outcomes Than Those Assessed By Urine Electrophoresis in Light Chain Multiple Myeloma Patients (2016) (0)
- Survival Improvement for Acute Myeloid Leukemia Patients Treated in Routine Practice By Intensive Chemotherapy Between 2000 and 2014 (2016) (0)
- Morphology of Bone Marrow Plasma Cells (BMPC) and Its Relationship with Interphase Cytogenetics and Prognosis in Multiple Myeloma (MM). (2009) (0)
- Impact of Genetic Abnormalities After Allogeneic Stem Cell Transplantation in Multiple Myeloma: Report of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire. (2009) (0)
- Allogeneic Hematopoietic Stem Cell Transplantation in First Line High Risk Multiple Myeloma Patients: Evolving Strategies with the Immunomodulating Drugs. (2012) (0)
- Closed form solution for time-varying Kalman filter (1995) (0)
- A First In-Depth Analysis of Alternate Splicing Landscape in Multiple Myeloma with Significant Potential Biological and Clinical Implications (2019) (0)
- Strategies for Risk-Adapted Therapy in Myeloma Multiple Myeloma (2007) (0)
- Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial (1999) (0)
- The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma (2019) (0)
- [Moschcowitz syndrome associated with Waldenström's disease]. (1990) (0)
- Are Stromal Cells of Adipose Tissue From Multiple Myeloma Patients Are Normal ? A Comparison of Adipose Derived Stromals Cells From Healthy Donors and Multiple Myeloma Patients (2012) (0)
- Transplant-related morbidity (TRM) in patients undergoing bone marrow transplantation (BMT): The role of preparative regimens (PR) (1997) (0)
- PET Evaluation Before Autografting Has a Strong Prognostic Impact in High-Risk, Relapsed Follicular Lymphoma Patients (2011) (0)
- Prognostic Factors Affecting Progression Free Survival For Multiple Myeloma Patients Receiving Lenalidomide Maintenance After Autologous Transplantation. Follow-Up Analysis Of The IFM 2005-02 Trial (2013) (0)
- multiple myeloma autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo followed by a dose-reduced allograft (IFM99-03 trial) with tandem Prospective comparison of autologous stem cell transplantation (2013) (0)
- Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19 (2021) (0)
- Drug Combinations with Transplantation for Myeloma. (2017) (0)
- Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry. (2007) (0)
- Double Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation: French Society of Bone Marrow Graft Transplantation and Cellular Therapy Experience (2008) (0)
- A Genome Wide Association Study Reveals Genetic Predisposition for Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma By Variation in the PREP1-Cbs Locus (2014) (0)
- Early allogeneic stem cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: An intent-to-treat analysis of the long-term experience of the BGMT group (2005) (0)
- The Intergroupe Francophone du Myélome experience with thalidomide (2009) (0)
- Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients (2008) (0)
- A Second Course of High-Dose Cytarabine before Autologous Stem Cell Transplantation Does Not Improve Outcome of Young Acute Myeloid Leukemia Patients in First Complete Remission: Results of the BGMT 95 Study. (2004) (0)
- DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma (2020) (0)
- Phase II Study of the Combination of Pomalidomide with Dexamethasone As Maintenance Therapy after First Relapse Treatment with PCD Followed or Not By Autologous Stem Cell Transplant in Multiple Myeloma Patients (2021) (0)
- Allogeneic H ematopoietic S tem-Cell T ransplantation A fter Nonmyeloablative P reparative R egimens: I mpact o f Pretransplantati on a nd P osttransplantat ion F actors on O utcome (2001) (0)
- Risk Factors for Overall Survival in Patients with Acute Myeloid Leukemia (AML) with Normal Karyotype Undergoing Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1): A Report On 366 Patients From the Acute Leukemia Working Party of EBMT (2012) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients Running title : GWAS in multiple myeloma pharmacogenomics (2016) (0)
- patients from the International Myeloma Working Group favorable features and shows better survival: an analysis of 10 549 Myeloma in patients younger than age 50 years presents with more (2008) (0)
- DNA hydroxymethylation reveals transcription regulation networks and prognostic signatures in multiple myeloma (2019) (0)
- How Treat How I treat fi rst relapse of myeloma (2017) (0)
- Comparison of Unrelated and Sibling Donor Allogeneic Hematopoietic Cell Transplantation (HCT) for Follicular Lymphoma (FL) - From the Lymphoma Working Party, European Group for Blood and Marrow Transplantation (EBMT) and Center for International Blood and Marrow Transplant Research (CIBMTR). (2009) (0)
- High Dose Therapy and Autologous Stem Cell Transplantation Still Improves Progression Free Survival in First Relapse for DLBCL in the Rituximab Era: A Study Using Patients as Their Own Controls. (2008) (0)
- Genomic Landscape Predictive of Minimal Residual Disease (MRD) in Multiple Myeloma (MM) (2015) (0)
- Chronic gvhd is increased after allo blood cell transplantation but is associated with a reduction of relapse rate: Results of a randomized study (2000) (0)
- elderly multiple myeloma patients ineligible for high-dose therapy Dexamethasone-based regimens versus melphalan-prednisone for (2011) (0)
- Comparison of Stromal Cells of Adipose Tissue From Multiple Myeloma Patients and Healthy Donors (2010) (0)
- High dose therapy and autologous stem cell transplantation in first relapse for dlbcl still improves progression free survival in the rituximab era. a retrospective analysis of the ebmt-lwp (2010) (0)
- Whole Exome Sequencing Of Multiple Myeloma Reveals An Heterogeneous Clonal Architecture and Genomic Evolution (2013) (0)
- Deciphering the chronology of copy number alterations in Multiple Myeloma (2018) (0)
- Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma. (2023) (0)
- Patients Under 50 Years of Age Do Not Present Specific Prognostic Characteristics: An IFM Study in 1897 Patients Under 65 Years of Age. (2009) (0)
- myeloma regardless of prior thalidomide exposure dexamethasone alone in patients with relapsed or refractory multiple Lenalidomide plus dexamethasone is more effective than (2008) (0)
- Acknowledgement to Reviewers 2015 (2015) (0)
- A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Multiple Myeloma Patients (2020) (0)
- Gene Mutations Detected by Whole-Exome Sequencing and Recurrent Cytogenetic Abnormalities Are Independent Events in Multiple Myeloma (2011) (0)
- The Role of In Vivo T-Cell Depletion On Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation From HLA-Identical Siblings in Patients with Follicular Lymphoma: An European Blood and Marrow Transplantation Study (2009) (0)
- Efficacy of Allogeneic Stem-Cell Transplantation for T/NK-Cell Lymphomas in Adults. (2007) (0)
- Sediment source control on fluvial sediment characteristics (2009) (0)
- Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (alloSCT) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLCL). A Retrospective Study from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) Registry. (2006) (0)
- Logic programming reveals alteration of key transcription factors in multiple myeloma (2017) (0)
- Molecular Prognosis in Multiple Myeloma: The IFM Experience. (2006) (0)
- Is allogeneic bone marrow transplantation the best treatment for young adult patients with acute myeloid leukemia in first complete remission. The BGMT Group. (1992) (0)
- Dysregulated Mirnas after Uniform Treatment Predict Outcome of Newly-Diagnosed Multiple Myeloma (2019) (0)
- Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma (2020) (0)
- Response Assignment Using Hevylite Correlates With Clinical Outcome in Multiple Myeloma (2017) (0)
- S119 THE ROLE OF RECURRENT SOMATIC ALTERATIONS IN THE NON-CODING GENOME WITH FUNCTIONAL IMPLICATIONS IN MM (2019) (0)
- Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project (2018) (0)
- Allogeneic stem cell transplantation (allo-SCT) from a HLA identical sibling for CR1 AML pts aged above 55 years old after a reduced intensity conditioning: A retrospective study from the Société Française de Greffe de Moelle et de thérapie cellulaire (SFGsm-TC) (2006) (0)
- Serum free light chain changes offer a more accurate assessment of response to therapy than urine Bence Jones protein excretion measurements in multiple myeloma (2015) (0)
- of the Intergroupe Francophone du Myélome Genetic abnormalities and survival in multiple myeloma: the experience (2011) (0)
- Improved outcome for AML patients over the years 2000–2014 (2017) (0)
- Growth Differentiation Factor 15 Plasma Level in patients with Multiple Myeloma: A Study of Intergroupe Francophone Du Myelome (2008) (0)
- In Myeloma, the Prognostic Impact of Hyperdiploidy Is Mainly Related to the Gain of Chromosome 5 (2008) (0)
- 160a Interstitial pneumonitis incidence during a fractionated total body irradiation: Results of an original digitized image processing (1995) (0)
- IL2 in Acute Leukemia (1996) (0)
- The impact of new drugs in the high dose strategy (2009) (0)
- Analysis of Downstream Changes In Mountain River Sediment Characteristics In Orogenic Context : A Way To Quantify Pebble Abrasion ? (2002) (0)
- Outcome at first relapse after frontline RVD regimen plus lenalidomide maintenance in transplant eligible MM patients. (2015) (0)
- Reply to J.C. Regelink et al (2010) (0)
- Prophylactic Vancomycin Averts Infection After Bone Marrow Transplant (1991) (0)
- Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-Dose Cyclophosphamide Versus Plerixafor. on Behalf of IFM (2016) (0)
- CR As Major End-Point After Consolidation for Multiple Myeloma Patients Eligible to High Dose Therapy (2011) (0)
- autologous stem cell transplantation treatment of multiple myeloma patients who are candidates for International Myeloma Working Group consensus approach to the (2012) (0)
- Abrogation of post-my e l o a b l a t i v e c h e m o t h e r a py neutropenia by ex-v i v o expanded autologous CD34-positive cells (1999) (0)
- The role of maintenance treatment in myeloma (2009) (0)
- Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study (2019) (0)
- Growth Differentation Factor 15 Is a Survival Factor for multiple myeloma cells and its plasma Concentration In Patients Is Related to Reduced Survival (2010) (0)
- Expressed fusion gene landscape and its impact in multiple myeloma (2017) (0)
- Microenvironment and Immunology Bioactivity and Prognostic Signi fi cance of Growth Differentiation Factor GDF 15 Secreted by Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma (2012) (0)
- Natural killer cell activity in bone marrow donors, correlation to HLA type and graft versus host disease.M-A Sol (1994) (0)
- WHOLE EXOME SEQUENCING DEFINES CLONAL ARCHITECTURE AND GENOMIC EVOLUTION IN MULTIPLE MYELOMA (2012) (0)
- S120 CHRONOLOGY OF COPY NUMBER ALTERATIONS FROM PRECURSORS TO MULTIPLE MYELOMA: WHAT COMES FIRST? (2019) (0)
- A051 Long-Term Follow-up Results of IFM9903 and IFM9904 Trials: RIC Versus ASCT (2009) (0)
- Comparison of the clinical sensitivity of two free light chain assays in a cohort of light chain multiple myeloma patients (2015) (0)
- Autologous BMT for post-remission therapy in adult ALL: an immunological approach. For The French Group of Therapy of Adult ALL. (1994) (0)
- [Veno-occlusive disease of the liver after bone marrow transplantation. Report of the symposium Autograft in France and the group of study of bone marrow transplantation. France Auto-Greffe et le Groupe d'Etude de la Greffe de Moelle osseuse]. (1994) (0)
- A415 RIC allo-SCT for Patients with High-Risk Myeloma: A Survey from the SFGM-TC (2009) (0)
- A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis (2016) (0)
- Optimization of immunohistochemical detection of P-glycoprotein in chronic lymphoid disorders. (1994) (0)
- A Phase 3 Randomized, Open-label Study of Isatuximab (SAR650984) Plus Pomalidomide (POM) and Dexamethasone (DEX) Versus POM and DEX in RRMM (2017) (0)
- Age-related trends in utilization and outcome of autologous haematopoietic cell transplantation for multiple myeloma. (2014) (0)
- Chemical vs. Physical Contributions to Grainsize Distributions in Hillslope Soils along a Denudation Gradient in the Sierra Nevada, California (2011) (0)
- Myeloperoxidase is involved in Vincristine resistance in human myeloblastic leukemia (1994) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Attal?
Michael Attal is affiliated with the following schools:
